Target intelligence / Profile preview

HLA-A*02:01-tyrosinase peptide complex (HLA-A*02:01/Tyr)

Target
HLA-A*02:01/Tyr
Molecular classification
MHC class I, Antigen-presenting molecule, Peptide-MHC complex
01

Overview

The HLA-A*02:01-tyrosinase peptide complex is a specific antigen-presenting structure formed by the association of the Human Leukocyte Antigen (HLA) allele A*02:01 and a peptide fragment derived from the tyrosinase enzyme (UniProt P01892; UniProt P14679). Tyrosinase is a copper-containing enzyme essential for melanin production and is highly expressed in melanocytes and melanoma cells, making it a prominent tumor-associated antigen (TAA). In patients carrying the HLA-A*02:01 allele, the immune system can recognize the tyrosinase-derived peptide, commonly the 369-377 sequence YMDGTMSQV, when it is presented on the cell surface within the MHC class I groove (PMID: 8145037). This complex is a primary target for cancer immunotherapies, including T-cell receptor (TCR) engineered T-cells and bispecific molecules like ImmTACs, which are designed to redirect T-cells to kill melanoma cells. While this target offers high specificity for melanocytic lineage cells, its presence in normal melanocytes can lead to on-target, off-tumor toxicities such as vitiligo or ocular inflammation. Consequently, it remains a significant focus for developing precision treatments for metastatic melanoma.

Other names
HLA-A2/TyrosinaseTyrosinase 369-377 peptide-HLA-A*02:01 complexMHC-peptide complex (HLA-A*02:01/Tyr)pMHC (HLA-A*02:01/YMDGTMSQV)
02

Mechanism of action

Recognition by T-cell receptors (TCRs) or TCR-like molecules leading to cytotoxic T-lymphocyte activation and lysis of target cells.

03

Biological functions

Antigen presentationImmune responseT-cell activation
04

Disease associations

Melanoma
05

Safety considerations

On-target off-tumor toxicity (vitiligo, uveitis)Cross-reactivity with similar self-peptidesCytokine release syndrome (CRS) in T-cell therapies
06

Interacting drugs

IMC-F10V

2 more in the full profile.

07

Biomarkers

HLA-A*02:01 genotypeTyrosinase expression in tumor tissue

Beyond the preview

Go deeper on HLA-A*02:01-tyrosinase peptide complex (HLA-A*02:01/Tyr).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA-A*02:01-tyrosinase peptide complex (HLA-A*02:01/Tyr).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call